Author of

• 36555

  +

  P86 - Targeted Therapy - Clinically Focused - New Target (ID 263)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Targeted Therapy - Clinically Focused
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36577

    +

    P86.15 - Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan (ID 3134)

    00:00 - 00:00  |  Presenting Author(s): Gee-Chen Chang
    • Abstract
    • Slides

    Introduction
    

    Osimertinib has demonstrated efficacy for patients with epidermal growth factor receptor (EGFR) T790M positive non-small cell lung cancer (NSCLC) in clinical trials. However, data on the effectiveness of osimertinib in real-world settings remain scarce.

    Methods
    

    This is a retrospective multi-center study, aimed at examining the effectiveness of osimertinib in patients who participated in the Early Access Program (EAP) in Taiwan. Locally advanced or metastatic NSCLC patients who had EGFR T790M mutation and progressive disease (PD) following at least one EGFR tyrosine kinase inhibitors (TKIs) were included. Patient clinical characteristics, T790M mutation testing platform and sample type, and post-osimertinib treatment were recorded by medical chart review .

    Results
    

    Of the 419 patients analyzed (mean age, 63 years; female, 67%), around half of them were heavily pretreated (53% received > 3 lines of therapy previously). All patients were EGFR T790M positive, confirmed through various sample types and testing platforms. The most common (> 10%) sample types were derived from tissue biopsy (44.2%), plasma (36.3%), and cytology (12.3%). The most common testing platforms were real-time PCR (44.2%) and MassARRAY (31.6%). The median progression free survival (PFS) was 10.5 months (95% CI: 8.95, 11.41), and 26.5% of patients survived without PD at 18 months. The median time to treatment discontinuation (TTD) was 11.9 months (95% CI: 10.49, 13.11) for osimertinib monotherapy and 14.5 months (95% CI: 12.16, 16.85) for osimertinib combined therapy. Of the 370 subsequent systemic treatments administered after the first dose of osimertinib, chemotherapy was the most common (289 in total; 125 were combined with osimertinib). The median overall survival (OS) was 19.0 months after receiving the first dose of osimertinib and 40.9% survived at 24 months. Lines of therapy did not have significant impact on PFS. Median PFS was 10.8 (95% CI: 8.59, 12.69), 13.6 (95% CI: 10.89, 16.3), and 9.2 (95% CI: 7.8, 10.62) months as second-, third-, and fourth-line (or more) therapy.

    Conclusion
    

    Overall, the clinical benefits of osimertinib were demonstrated in EGFR T790M positive NSCLC patients in the real-world setting.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.